Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma

Table 1

Patients’ characteristics ().

Characteristic		N (%)
Gender	Male	151 (75.9)
	Female	48 (24.1)
Age	Median (25%–75%)	66 (58–72)
Stage	I	13 (6.5)
	II	53 (26.6)
	III	61 (30.7)
	IV	54 (27.1)
	Peritoneal	18 (9.0)
Histological type	Epithelioid	143 (71.9)
	Biphasic	25 (12.6)
	Sarcomatoid	21 (10.6)
	Not characterized	10 (5.0)
ECOG performance status	0	10 (5.0)
	1	95 (47.7)
	2	84 (42.2)
	3	10 (5.0)
C-reactive protein	Median (25%–75%)	23 (10–68.3) [29]
Asbestos exposure	Not exposed	43 (22.3) [6]
	Exposed	150 (77.7)
Smoking	Nonsmokers	95 (49.0) [5]
	Smokers	99 (51.0)
Type of chemotherapy	Gemcitabine/cisplatin	123 (61.8)
	Pemetrexed/cisplatin	48 (24.1)
	Other	11 (5.5)
	None	17 (8.6)
Response rate	CR	7 (4.1) [27]
	PR	57 (33.1)
	SD	86 (50.0)
	PD	22 (12.8)
Time to progression	Median (25%–75%)	7.67 (5.27–13.80)
Overall survival	Median (25%–75%)	16.30 (9.07–26.80)
Follow-up	Median (25%–75%)	69.67 (22.00–81.53)

Numbers in square brackets denote the number of patients with missing data. CR: complete response; ECOG: Eastern Cooperative Oncology Group; PD: progressive disease; PR: partial response; SD: stable disease.